Skip to main content

Baker Bros. Advisors LP's Form 4 filing

Madrigal Pharmaceuticals, Inc. (MDGL) · filed Mar 25, 2024

Accession no.
0000950170-24-035941
Filed
Mar 25, 2024
Trade date
Mar 21, 2024
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 2 derivative transactions. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Baker Bros. Advisors LPCIK 0001263508Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

This filing has no transactions of this kind.

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 21, 2024Common StockPPurchaseAcquired+86,741$260.00+$22,552,660212,188Indirect
Mar 21, 2024Common StockPPurchaseAcquired+970,951$260.00+$252,447,2602,493,602Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Remarks

Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC, and Dr. Raymond Cheong, a full-time employee of Baker Bros. Advisors LP, are directors of Madrigal Pharmaceuticals, Inc. (the "Issuer"). By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons other than Julian C. Baker are deemed directors by deputization of the Issuer.

Read the full filing on SEC EDGAR (opens in a new tab)